4-(4-chloro-6-formyl-phenyl)-piperazine-1-carboxylic acid tert-butyl ester | 869478-16-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4-(4-chloro-6-formyl-phenyl)-piperazine-1-carboxylic acid tert-butyl ester
• 英文别名: 2-[4-(tert-butoxycarbonyl)-1-piperazinyl]-5-chlorobenzaldehyde；4-(4-chloro-2-formyl-phenyl)-piperazine-1-carboxylic acid tert-butyl ester；tert-butyl 4-(4-chloro-2-formylphenyl)tetrahydro-1(2H)-pyrazinecarboxylate；tert-butyl 4-(4-chloro-2-formylphenyl)piperazine-1-carboxylate
• CAS: 869478-16-0
• 化学式: C₁₆H₂₁ClN₂O₃
• 分子量: 324.807
• InChiKey: QYUKBCDPNJYYKP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  49.8
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  4-(4-chloro-6-formyl-phenyl)-piperazine-1-carboxylic acid tert-butyl ester 在 titanium(IV) tetraethanolate 、 三甲基铝 作用下， 以 四氢呋喃 、 乙醇 、 正庚烷 、 甲苯 为溶剂， 反应 17.0h， 生成 4-{4-chloro-2-[(R)-3-methyl-1-((S_S)-2-methyl-propane-2-sulfinylamino)-butyl]-phenyl}-piperazine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Practical Asymmetric Synthesis of α-Branched 2-Piperazinylbenzylamines by 1,2-Additions of Organometallic Reagents to N-tert-Butanesulfinyl Imines

  摘要：

  2-[4-(tert-Butoxycarbonyl)piperazinyl]benzylidene-tert-butanesulfinamides underwent nucleophilic 1,2-addition with different organometallic reagents to give highly diastereomerically enriched adducts. X-ray crystallography of the resulting alpha-branched N-Boc-2-piperazinylbenzyl-tert-butanesulfinamides confirms different mechanisms depending on the organometallic reagent used. Differential deprotection of the N-Boc and the tert-butanesulfinamides was investigated, and the dehydration byproducts have been identified and characterized. To avoid the formation of byproducts in the acidic deprotection step, the N-tert-butanesulfinamide group was converted to the corresponding N-tert-butanesulfonamide (Bus), which allowed for clean orthogonal deprotection. The efficient synthesis and deprotection of the N-Boc-2-piperazinylbenzyl-tert-butanesulfinamides herein described constitutes an attractive method for extensive structure-activity studies in the search for novel ligands of the human melanocortin 4 receptor.

  DOI：

  10.1021/jo051514p
• 作为产物：
  描述：

  2-(1-piperazinyl)-5-chlorobenzaldehyde 、 二碳酸二叔丁酯 在 碳酸氢钠 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 3.0h， 以43 g的产率得到4-(4-chloro-6-formyl-phenyl)-piperazine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Design, Synthesis, In Vitro, and In Vivo Characterization of Phenylpiperazines and Pyridinylpiperazines as Potent and Selective Antagonists of the Melanocortin-4 Receptor

  摘要：

  Benzylamine and pyridinemethylamine derivatives were synthesized and characterized as potent and selective antagonists of the melanocortin-4 receptor (MC4R). These compounds were also profiled in rodents for their pharmacokinetic properties. Two compounds with diversified profiles in chemical structure, pharmacological activities, and pharmacokinetics, 10 and 12b, showed efficacy in an established murine cachexia model. For example, 12b had a K-i value of 3.4 nM at MC4R, was more than 200-fold selective over MC3R, and had a good pharmacokinetic profile in mice, including high brain penetration. Moreover, 12b was able to stimulate food intake in the tumor-bearing mice and reverse their lean body mass loss. Our results provided further evidence that a potent and selective MC4R antagonist with appropriate pharmacokinetic properties might potentially be useful for the treatment of cancer cachexia.

  DOI：

  10.1021/jm701137s

文献信息

• Spiroindolinone Derivatives
  申请人：Chen Li

  公开号：US20090163512A1

  公开（公告）日：2009-06-25

  There are provided compounds of the formula and pharmaceutically acceptable salts and esters and enantiomers thereof wherein W, X, X′, Y, V, V′, A, B and R are as described herein. The compounds have utility as antiproliferative agents, especially, as anticancer agents.

  提供的化合物具有以下公式和其药用可接受的盐、酯和对映体，其中W、X、X′、Y、V、V′、A、B和R如本文所述。这些化合物可用作抗增殖剂，特别是抗癌剂。
• Spiroindolinone derivatives
  申请人：Hoffman-La Roche Inc.

  公开号：US07776875B2

  公开（公告）日：2010-08-17

  There are provided compounds of the formula and pharmaceutically acceptable salts and esters and enantiomers thereof wherein W, X, X′, Y, V, V′, A, B and R are as described herein. The compounds have utility as antiproliferative agents, especially, as anticancer agents.

  提供了以下公式化合物及其药学上可接受的盐和酯以及其对映体，其中W、X、X'、Y、V、V'、A、B和R的描述如下。这些化合物具有抗增生剂的功效，尤其是作为抗癌剂。
• [EN] FUSED TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF<br/>[FR] DÉRIVÉ TRICYCLIQUE CONDENSÉ, SON PROCÉDÉ DE PRÉPARATION ET SON APPLICATION PHARMACEUTIQUE<br/>[ZH] 并三环类衍生物、其制备方法及其在医药上的应用
  申请人：SHENZHEN SALUBRIS PHARM CO LTD

  公开号：WO2022007866A1

  公开（公告）日：2022-01-13

  一种涉及化学药物技术领域的并三环类衍生物、其制备方法及其在医药上的应用。所述并三环类衍生物是蛋白聚糖酶2(ADAMTS-5，Aggrecanase-2)的抑制剂。一种包含这些化合物的药物组合物以及将该化合物用于制备治疗骨关节炎等疾病的药物中的用途。
• SPIROINDOLINONE DERIVATIVES AS ANTICANCER AGENTS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2235017A1

  公开（公告）日：2010-10-06
• US7776875B2
  申请人：——

  公开号：US7776875B2

  公开（公告）日：2010-08-17